On the historic date of December 1, 2024, Suzhou played host to a monumental occasion. Wecare Probiotics and APC Microbiome Institute (Ireland) came together to celebrate the signing of a strategic partnership aimed at advancing probiotics for infant health. This collaboration not only marks a deep scientific engagement between the two entities but also heralds a significant breakthrough in global infant health.

Remodeling the intestinal microbiota is helpful for the treatment of T2DM. Probiotics can regulate the gut microbiota in the intestinal tract through colonization.

Wecare Probiotics Co., Ltd., a leader in probiotic research and innovation, is thrilled to highlight a groundbreaking study that showcases the potential of probiotics in supporting post-menopausal women's health.

The science surrounding Akkermansia muciniphila is rapidly advancing, revealing its significant potential in supporting metabolic health, enhancing gut barrier function, and modulating inflammation.

This invention pertains to a probiotic composition designed to promote development and height increase, containing two strains: Bifidobacterium longum subsp. longum BL21 and Bifidobacterium breve BBr16.

This probiotic combination shows promise as a preventive and therapeutic agent for oral health, especially in mitigating pathogenic bacterial growth and reducing inflammation in periodontal disease.